What's new

[PIO] ECDC and EMA update recommendations on additional booster doses of COVID-19 vaccines

29100.jpg




The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) recommend a second booster dose of COVID-19 mRNA vaccines for people aged 60 to 79 years and people with medical conditions that put them at high risk of serious disease.

In April 2022, the EMA and ECDC had recommended a second booster dose in people over 80 years of age. However, the two agencies had noted at the time that if there is a resurgence of infections it may be necessary to evaluate the administration of second booster doses in people aged 60 to 79 years as well as in vulnerable people of any age.

Second booster dose for people over 60 years of age and vulnerable people

As a new wave is underway in Europe, with increasing rates of hospital and intensive care unit (ICU) admissions, it is critical that public health authorities consider the administration of a second booster dose to people aged 60 to 79 years as well as to vulnerable people of all ages. The second booster dose could be given at least four months after the previous one, with a focus on people who have received the previous booster dose for more than 6 months. In the context of emerging variants of SARS-CoV-2, currently licensed vaccines remain highly effective in reducing hospitalizations, severe disease and deaths due to COVID-19.

Stella Kyriakidou, the European Union Commissioner for Health and Food Safety, said "Anti-COVID-19 vaccines work and offer good levels of protection against severe disease and hospitalization. As cases and hospitalisations increase again as we enter the summer season, I urge everyone to get vaccinated and receive the booster dose as soon as possible. There is no time to lose."

"I call on Member States to immediately start providing second booster doses to everyone over the age of 60 and all vulnerable people, and I urge those who are eligible to be vaccinated. In doing so, we will protect ourselves, our loved ones and vulnerable populations."

"We are currently seeing increasing rates of case reporting with COVID-19 and an increasing trend in patient admissions and occupancy in hospitals and ICUs in several countries, mainly due to the Omicron BA variant.5" said Dr Andrea Ammon, Director of the ECDC.

"This marks the start of a new, widespread wave of COVID-19 disease across the European Union. There are still too many people at risk of serious COVID-19 disease who we need to protect as soon as possible. We need to remind people of the importance of vaccination from the first vaccine to the second booster dose. We need to start today."

"We expect that adults 60 years and older and medically vulnerable populations will need a second booster dose. These are the groups most at risk of severe disease, and giving a second booster dose to these groups now will prevent a significant number of hospitalizations and deaths from COVID-19.

"I know that a significant effort by public health authorities and society at large is required to achieve this goal. But now at the beginning of a new wave is the time to make the extra effort. We have enough safe and effective vaccines and every COVID-19 infection prevented now is a potential life saved."

Second booster dose in the general population

At present, there is no clear evidence to support the administration of a second booster dose to people under 60 years of age who are not at high risk of serious disease. There is also no clear evidence to support the administration of an early second booster dose to healthcare workers or those working in long-term care homes, unless they are at high risk.

However, those residing in long-term care homes are likely to be at risk of severe disease and should be considered for a second booster dose in accordance with national recommendations.

The ECDC and EMA have asked public health authorities across the EU to plan for the administration of additional booster doses in the autumn and winter period to people at higher risk of severe disease, possibly combining vaccinations for COVID-19 with those for influenza.

National Immunisation Technical Advisory Groups (NITAGs) will ultimately make national decisions on who should receive second booster doses, taking into account the situation in their countries.

Adapted vaccines

The latest recommendations from ECDC/EMA come amid work to adapt vaccines for Omicron variants of concern.

"We are working towards possible approvals of adapted vaccines in September," said EMA Executive Director Emer Cooke, noting that "The Committee for Medicinal Products for Human Use is currently evaluating data for two adapted vaccines."

"In the interim, it is important to consider the use of currently licensed vaccines as a second booster dose in individuals who are more vulnerable. EU licensed vaccines continue to be effective in preventing hospitalisations, severe disease and deaths from COVID-19, even as new variants and sub-variants continue to emerge."

He added that "EU authorities are working closely with the World Health Organization and international partners on policies related to tailored vaccines."

The ECDC and EMA will continue to closely evaluate vaccine effectiveness and epidemiological data and will update their recommendations accordingly. Further details on the most recent recommendations on second booster doses are available in the ECDC/EMA joint statement.

(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO

Source

[/p

 
Back
Top